LG
Ligand Pharmaceuticals, Inc.
LGNZZ · OTC
$0.07 -7.14% (-$0.01)
1M -14.29%
Market Cap $1.30M
P/E Ratio 0.01x
Div. Yield -
ROE 20.06%
Bulios Fair Price
$0.09
38.5% upside
Current Price
$0.065
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LGNZZ is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
100 /100
Cheap EV/EBITDA 0.74x
P/S 0.00x
P/B 0.00x
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
100 /100
Strong Net margin 67.88%
Op. margin 34.45%
FCF margin 45.24%
Quality
49 /100
Average ROE 20.06%
ROA 9.02%
Asset turnover 0.13x
Debt
81 /100
Low Current ratio 30.49x
Int. coverage 51.04x
Net debt/EBITDA 0.73x
Stability
91 /100
Stable Beta 0.98x
EPS volatility N/A
Profitable years N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LGNZZ
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Todd C. Davis
Employees
47
Headquarters
Jupiter
Upcoming events
05 NOV
Earnings
Upcoming earnings report